Complete Story
01/16/2017
NCCN has published updates to the NCCN Chemotherapy Order Templates
The following NEW chemotherapy order templates have been published: o NSC64 – Pembrolizumab o NSC65 – Gefitinib o NSC66 – Osimertinib o NSC67 – Alectinib o NSC69 – Afatinib + Cetuximab o NSC70 – Atezolizumab o NSC71 – PACLItaxel/CARBOplatin (previously part of NSC29) o NSC72 – Gemcitabine/CISplatin (previously part of NSC32) o NSC73 – CISplatin/DOCEtaxel (previously part of NSC33) o NSC74 – Pemetrexed/CISplatin (previously part of NSC43) Indications for the following templates have been updated: o NSC1 – CISplatin/VinORELBine Every 28 Days o NSC3 – CISplatin/VinORELBine Every 21 Days o NSC7 – CISplatin/VinBLAStine with Concurrent Radiation o NSC11a – PACLItaxel/CARBOplatin with Concurrent Radiation followed by PACLItaxel/CARBOplatin – PACLItaxel/CARBOplatin with Concurrent Radiation Course o NSC11b – PACLItaxel/CARBOplatin with Concurrent Radiation followed by PACLItaxel/CARBOplatin – PACLItaxel/CARBOplatin Course o NSC27 – Erlotinib o NSC29 – PACLItaxel/CARBOplatin o NSC32 – Gemcitabine/CISplatin o NSC33 – CISplatin/DOCEtaxel o NSC43 – Pemetrexed/CISplatin o NSC51 – Crizotinib o NSC52 – CARBOplatin/Pemetrexed with Concurrent Radiation o NSC53 – CISplatin/Pemetrexed with Concurrent Radiation o NSC58 – CISplatin/Etoposide with Concurrent Radiation Cycle information for the following templates has been updated to include “for 4–6 cycles (first line therapy), or until disease progression or unacceptable toxicity (subsequent therapy)” for the advanced, recurrent, or metastatic setting o NSC17, 18, 20, 26, 28, 30, 31, 36, 38, 41, 48, 49, 54, 57, 62 Regimen information and references for the following template have been updated: o NSC53 – CISplatin/Pemetrexed with Concurrent Radiation NCCN has published updates to the NCCN Templates® for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) to reflect the currently published NCCN Guidelines® for CLL/SLL. The following templates have been deleted: o CLL13 – Fludarabine o CLL19 – Fludarabine + Alemtuzumab o CLL50 – Cyclophosphamide/PredniSONE + Rituximab o CLL51 – Cladribine o CLL53 – Cyclophosphamide/PredniSONE NCCN has published updates to the NCCN Templates for Myelodysplastic Syndromes (MDS) to reflect the currently published NCCN Guidelines for MDS. Regimen information and references for the following templates have been updated: o MDS2 – Azacitidine o MDS4 – Decitabine o MDS5 – ATG (Antithymocyte globulin, equine)/Cyclosporine o MDS6 – ATG (Antithymocyte globulin, equine) The following template has been deleted: o MDS7 – Cyclosporine For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Templates, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org. To view the NCCN Guidelines for Patients®, please visit NCCN.org/patients. Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps. |
Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!